



TWBM

Taiwan Biomaterial Company

**台灣生醫材料公司(6649)
法人說明會**

2021.09.14

Disclaimer

- The information contained in this confidential document (“Presentation”) has been prepared by Taiwan Biomaterial Co., Ltd. (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

公司基本資料

■ 產品項目：

泡沫式人工腦膜、腦中風血栓負壓移除導管系統、退化性關節炎組織修復再生產品及其他高階植入式醫療器材

■ 技術來源：工業技術研究院

■ 公司設立時間：2012年11月12日

■ 公司地點：新竹生物醫學園區

■ 資本額：新台幣3.3億元

■ 董事長：林志茂

■ 總經理：廖俊仁

■ 員工人數：29人



商業模式

Transforming Clinical Concept to Medical Product



臨床需求


台灣生醫材料

國際品牌大廠

聚焦於**臨床需求到產品上市**之價值創造


高價值(金錢)醫材選題能力

由臨床需求確認高價值醫材產品



高階醫材完整開發經驗

Medical Device GMP Plant (ISO13485) & Product



FDA



CE

台生材產品標的策略

☑ **Me only** 產品
(世界第一原創產品)

☑ **Me better** 產品
(世界前三名，美國市場有需求產品)

創新產品佈局

與矽谷公司合作開發



台生材自主研發



創新產品佈局

與矽谷公司合作開發

- 腦中風血栓負壓移除導管系統
-- 負壓幫浦系統、鎳鈦導絲

台生材自主研發

● 泡沫式人工腦膜

● 退化性關節炎組織修復再生產品

2016



2018

2020

2022

人工腦膜修復產品





Remove the dura mater during neurosurgery



全球人工腦膜市場總值**4.8億美元**

臨床需求: 腦膜修補及防止腦脊髓液滲漏


泡沫式人工腦膜(Foamagen)




產品優勢: 無化學添加劑及3分鐘可成膠之創新人工腦膜

產品進度: 已取得台灣上市許可，已進入十四家醫院銷售中；
通過美國IDE許可，將進行314例人體臨床試驗。

腦中風治療醫材




Hemorrhagic Stroke




Blood begins to fill the space inside the brain

- Occurs when a weakened blood vessel ruptures, allowing blood to leak inside brain



Ischemic Stroke





- Occurs when clot cuts off blood supply to brain, causing brain cells and tissue to die in minutes

Source: <http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/>

美國每年80萬人/年發生; **50%失能**; **經濟損失650億美金**
87%為**缺血性**中風; 美國有**7億美金/年**市場規模

腦中風血栓負壓移除導管系統




腦血管專用吸管
ICI

腦中風血塊吸除幫浦
TWBM

技術優勢: 可吸除**深層**腦中風**血塊**之**取栓**系統


產品進度: 導管及幫浦耗材取得美國產品上市許可，已銷售到美國腦中風治療中心

退化性關節炎



發生率: **11.3%**; 全球市場值: **59億美元**
目前除置換**人工關節**並無有效治療方式

退化性關節炎組織處理修復技術



無組織處理



組織處理



技術優勢: 利用微創醫材將早期退化性關節炎軟骨進行 **酵素組織處理** 使軟骨修復再生

產品進度: 已通過醫院IRB並向衛福部申請22例人體臨床研究許可審查中，將導入人體臨床研究試驗。



investor@twbm.com.tw
+886-3-6683088